Иммунотерапия метастатического почечно-клеточного рака

1. Hock L.M., Lynch J., Balaji K.C. Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of surveillance, epidemiology and end results program data // J. Urol. — 2002; 167: 57—60.

2. Negrier S., Maral J., Drevon et al. Long term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant IL-2 in Europe // Cancer J. Sci. Am. — 2000; 6(suppl 1): 93—98.

3. Law T.M., Motzer R.J., Mazumdar M. et al. Phase III randomized trial of IL-2 with or without LAK cells in the treatment of patients with advanced renal cell carcinoma // Cancer. — 1995; 76: 824—832.

4. Lee D.S., White D.E, Hurst R. et al. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to IL-2-based immunotherapy // Cancer J. Sci. Am. — 1998; 4: 86—93.

5. Fisher R.I., Rosenberg S.A., Fyfe G. et al. Longterm survival update for high-dose recombinant IL-2 in patients with renal cell carcinoma // Cancer J. Sci. Am. — 2000; 6 (suppl 1): 55—57.

6. Ulchaker J., Panuto J., Rayman P. et al. IF-gamma production by T-lymphocytes from renal cell carcinoma patients: evidence of impaired secretion in response to IL-12 // J. Immunother. — 1999; 22: 71—79.

7. Kudoh S., Redovan C., Rayman P. et al. Defective granzyme B gene expression and lytic response in T lymphocytes infiltrating human renal cell carcinoma // J. Immunother. — 1997; 20: 479—487.

8. Lauerova L., Dusek L., Simickova M. et al. Renal cell carcinoma –associated immune impairment that may interfere with the response to cytokine therapy // Neoplasma. — 1999; 46: 141—149.

9. Almand B., Clark J.I., Nikitina E. et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppresion in cancer // J. Immunol. — 2001; 166: 678—689.

10. Tso C.I., Zisman A., Pantuck A. et al. Induction of G 250-targeted and T-cell mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and GM-CSF // Cancer. Res. — 2001; 61: 7925—7933.

11. Patel N.P., Lavengood R.W. Renal cell carcinoma; natural history and results of treatment // J. Urol. — 1978; 199: 722—726.

12. Motzer R.J., Bander N.H., Nanus D.M. Renal-cell carcinoma // N. Engl. J. Med. — 1996; 335: 865—875.

13. Piltz S., Meimarakis G., Wichmann M.W. et al. Long-term results after pulmonary resection of renal cell carcinoma metastases // Ann. Thorac. Surg. — 2002; 73: 1082—1087.

14. Flanigan R.C., Salmon S.E., Blumenstein B.A. et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2f alone for metastatic renal cell cancer // N. Engl. J. Med. — 2001; 345: 1655—1659.

15. Mickisch G.H., Garin A., Van Poppel H. et al. Radical nephrectomy plus IF-alfa based immunotherapy compared with IF-alfa alone in metastatic renal cell carcinoma: a randomised trial // Lancet. — 2001; 358: 966—970.

16. Motzer R.J., Mazumdar M., Bacik J. et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma // J. Clin. Oncol. — 1999; 17: 2530—2540.

17. Zisman A., Pantuck A.J., Dorey F. et al. Mathematical Model to predict individual survival for patients with renal cell carcinoma // J. Clin. Oncol. — 2002; 1368—1374.

18. Naitoh J., Kaplan A., Dorey F. et al. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy // J. Urol. 1999; 162: 46—50.

19. Walther M.M., Lyne J.C., Libutti S.K. et al. Laparoscopic cytoreductive nephrectomy as preparation for administration of systemic IL-2 in the treatment of metastatic renal cell carcinoma: a pilot study // Urology. — 1999; 53: 496—501.

20. Wagner J.R., Walther M.M., Linehan W.M. et al. IL-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place. // J. Urol. — 1999; 162: 43—45.

21. Whitney R.B., Levy J.G., Smith A.G. Influence of tumor size and surgical resection on cell-mediated immunity in mice // J. Natl. Cancer. Inst. — 1974; 53: 111—116.

22. Musselman D.L., Lawson D.H., Gummick J.F. et al. Paroxetine for the prevention of depression induced by high-dose interferon-alfa // N. Engl. J. Med. — 2001; 344: 961—966.

23. Schwartzentruber D.J. Guidelines for the safe administration of high-dose IL-2 // J. Immunother. — 2001; 24: 287—293.

24. Hoffman D., Gitlitz B., Moldawer N. et al. High dose bolus IL-2 in a non-intensive care unit setting for metastatic renal cell carcinoma: UCLA Kidney Cancer Program // Proc. Annu Meet Am. Soc. Clin. Oncol. — 2000; 1357 Abstract.

25. Negrier S., Escudier B., Lasset C. et al. Recombinant human IL-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d’Immunotherapie // N. Engl. J. Med. — 1998; 338 :1272—1278.

26. Weiss G.R., Margolin K.A., Aronson F.R. et al. A randomized phase II trial of continous infusion IL-2 or bolus injection IL-2 plus LAK for advanced renal cell carcinoma // J. Clin. Oncol. — 1992; 10: 275—281.

27. Ier S., Caty A., Lesimple T. et al. Treatment of patients with metastatic renal cell carcinoma with a combination of subcutaneous IL-2 and IF-alfa with or without fluoro-uracil. Groupe Francais d’Immunotherapie. Federation Nationale des Centres de Lutte Contre Le cancer // J. Clin. Oncol. — 2000; 18 : 4009—4015.

28. Atzpodien J., Kirchner H., Illiger H.J. et al. IL-2 in combination with IF-alfa and 5-FU versus Tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomised clinical trial // Br. J. Cancer. — 2001; 85:1130—1136.

29. Fossa S.D. Interferon in metastatic renal cell carcinoma // Semin. Oncol. — 2000; 27: 187—193.

30. Pfeffer L.m., Wang C., Constantinescy S.N. et al. Human renal cancers resistant to IFN’s antiproliferative action exhibit sensitivity to IFN’s gene-inducing and antiviral actions // J. Urol. 1996; 156: 1867—1871.

31. Albini A., Marchisone C., Del Grosso F. et al. Inhibition of angiogenesis and vascular tumor growth by interferon-producing cells: a gene therapy approach // Am. J. Pathol. — 2000; 156: 1381—1393.

32. Motzer R.J., Mazumdar M., Bacik J. et al. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. // J. Clin. Oncol. — 2000; 18: 1928—1935.

33. Pizzocaro G., Piva L., Colavita M. et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomised study // J. Сlin. Oncol. — 2001; 19: 422—4231.

34. Henriksson R., Nilsson S., Colleen S. et al. Survival in renal cell carcinoma: a randomized evaluation of tamoxifen vs IL-2, IFN-alfa (Leucocyte) and tamoxifen // Br. J. Cancer . — 1998; 77: 1311—1317.

35. Daniels G.A., Galanis E. Immunotherapy of renal cell carcinoma by intratumoral administration of an IL-2 cDNA/DMRIE/DOPE lipid complex // Curr. Opin. Mol. Ther. — 2001; 3: 70—76.

36. Motzer R.J., Rakhit A., Ginsberg M. et al. Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma // J. Clin. Oncol. — 2001; 19: 1312—1319.

37. Yang J.C., Topalian S.L., Schwartzentruber D.J. et al. The use of polyethylene glycol-modified IL-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2 // Cancer. — 1995; 76: 687—694.

38. Kedar E., Gur H. Babai I. et al. Delivery of cytokines by liposomes; hematopoietic and immunomodulatory activity of IL-2 encapsulated in conventional liposomes and in long-circulating liposomes // J. Immunother. 2000; 23: 131—145.

39. Shanafelt A.B., Lin Y., Shanafelt M.C. et al. A T-cell selective IL-2 mutein exhibits potent antitumor activity and is well tolerated in vivo // Nat. Biotechnol. — 2000; 18: 1197—1202.

40. Schwaab T., Heaney J.A., Schned A.R. et al. A randomised phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon-gamma and human recombinant alpha-2b therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters // J. Urol. — 2000; 163: 1322—1327.

41. Tate J., Olencki T., Finke J. et al. Phase I trial of simultaneously administered GM-CSF and IL-6 in patients with renal cell carcinoma: clinical and laboratory effects // Ann. Oncol. — 2001; 12: 655—659.

42. Fishman M., Seigne J., Antonia S. Novel therapies for renal cell carcinoma // Expert Opin. Investig. Drugs. — 2001; 10 : 1033—1044.

43. Jiang F., Desper R., Papadimitriou C.H. et al. Construction of evolutionary tree models for renal cell carcinoma from comparative genomic hybridisation data // Cancer Res. — 2000; 60: 6503—6509.

44. Caudill M.M., Li Z. HSPPC-96: a personalised cancer vaccine // Expert. Opin. Biol. Ther. — 2001; 1: 539—547.

45. Antonia S.J., Seigne J., Diaz J. et al. Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic IL-2 in patients with metastatic renal cell carci-noma // J. Urol. 2002; 167: 1995—2000.

46. Wiseman G.A., Scott A.M., Lee F-T. et al. Chimeric G250 (cG250) monoclonal antibody Phase I dose escalation trial in patients with advanced renal cell carcinoma (RCC) // Proc. Annu. Meet. Am. Soc. Clin. Oncol. — 2001; 1027. Abstract.

47. Schwartz G., Dutcher J.P., Vogelzang N.J. et al. Phase II clinical trial evaluating the safety and effectiveness of ABX-EGF in renal cell cancer (RCC) // Proc. Annu. Meet. Am. Soc. Clin. Oncol. — 2002; 91. Abstract.

48. Yang J.C., Haworth L., Steinberg S.M. et al. A randomized double-blind placebo controlled trial of bevacizumab (anti-VEGF antibody) demonstrating a prolongation in time to progression in patients with metastatic renal cancer // Proc. Annu. Meet. Am. Soc. Clin. Oncol. 2002; 15.

49. Holden S.A., Lan Y., Pardo A.M. et al. Augmentation of antitumor activity of an antibody-IL-2 immunocytokine with chemotherapeutic agents // Clin. Cancer. Res. — 2001; 7: 2862—2869.

50. Carnemolla B., Borsi L., Balza E. et al. Enhancement of the antitumor properties of IL-2 by its targeted delivery to the tumor blood vessel extracellular matrix // Blood. — 2002; 99: 1659—1665.

51. Figlin R.A., Thompson J.A., Bukowski R.M. et al. Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymhocytes in combination with recombinant IL-2 in metastatic renal cell carcinoma // J. Сlin. Oncol. 1999; 17: 2521—2529.

52. Rosenberg S.A., Lotze M.T., Yang J.C. et al. Prospective randomised trial of high-dose IL-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer //J. Natl. Cancer. Inst. — 1993; 85: 622—632.

53. Childs R., Chernoff A., Contentin N. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation // N. Engl. J. Med. — 2000; 343:750—758.

54. Rini B.I., Zimmerman T., Stadler W.M. et al. Allogeneic stemcell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results // J. Clin. Oncol. — 2002; 20: 2017—2024.v